Claims

1. A vaccine combination comprising

   (i) a first composition comprising an immunologically effective amount of an adenovirus vector comprising a nucleic acid encoding an antigenic protein of a first filovirus subtype, together with a pharmaceutically acceptable carrier; and

   (ii) a second composition comprising an immunologically effective amount of an MVA vector comprising a nucleic acid encoding antigenic proteins of at least two filovirus subtypes, together with a pharmaceutically acceptable carrier;

   wherein one of the compositions is a priming composition and the other composition is a boosting composition.

2. A vaccine combination according to claim 1, wherein the first composition (i) further comprises an adenovirus vector comprising a nucleic acid encoding an antigenic protein of a second filovirus subtype.

3. A vaccine combination according to claim 2, wherein the first composition (i) further comprises an adenovirus vector comprising a nucleic acid encoding an antigenic protein of a third filovirus subtype.

4. A vaccine combination according to claim 1, wherein the adenovirus vector in the first composition (i) comprises a nucleic acid encoding an antigenic protein with SEQ ID NO:1.

5. A vaccine combination according to claim 4, wherein composition (i) further comprises an adenovirus comprising a nucleic acid encoding an antigenic protein with SEQ ID NO:2.

6. A vaccine combination according to claim 5, wherein composition (i) further comprises an adenovirus comprising a nucleic acid encoding an antigenic protein with SEQ ID NO:3.

7. A vaccine combination according to any one of claims 1-6, wherein the MVA vector in

composition (ii) comprises a nucleic acid encoding antigenic proteins of at least four filovirus subtypes.

8. A vaccine combination according to any one of claims 1-7, wherein the MVA vector in composition (ii) comprises a nucleic acid encoding antigenic proteins from four different filovirus subtypes having SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 4, and SEQ ID NO: 5.

9. A vaccine combination according to any one of claims 1-8, wherein the adenovirus vectors are rAd26 or rAd35 vectors.

10. A vaccine combination according to any one of claims 1-9 for use in generating a protective immune response against at least one filovirus subtype, wherein the first composition is to be used for priming said immune response and the second composition is to be used for boosting said immune response.

11. A vaccine combination according to any one of claims 1-9 for use in generating a protective immune response against at least one filovirus subtype, wherein the second composition is to be used for priming said immune response and the first composition is to be used for boosting said immune response.

12. A vaccine combination according to any one of claims 1-9 for use in the preparation of a pharmaceutical composition or medicament.

13. A kit comprising the vaccine combination according to any one of claims 1-9, wherein one of the compositions is a priming composition and the other composition is a boosting composition.

14. A kit according to claim 13 for use in generating a protective immune response against at least one filovirus subtype, wherein the first composition is to be used for priming said immune response and the second composition is to be used for boosting said immune response.

15. Use of a first composition comprising an immunologically effective amount of an adenovirus vector comprising a nucleic acid encoding an antigenic protein of a first filovirus subtype, together with a pharmaceutically acceptable carrier; and a second

composition comprising an immunologically effective amount of an MVA vector comprising a nucleic acid encoding antigenic proteins of at least two filovirus subtypes, together with a pharmaceutically acceptable carrier; each in the manufacture of a medicament which when used in combination, is for the treatment of a filovirus infection wherein one of the compositions is a priming composition and the other composition is a boosting composition.